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Abstract: Adjuvants enhance immunogenicity of vaccines through either targeted antigen 
delivery or stimulation of immune receptors. Three cationic nanoparticle formulations were 
evaluated for their potential as carriers for a DNA vaccine, and muramyl dipeptide (MDP) 
as immunostimulatory agent, to induce and increase immunogenicity of Mycobacterium 
tuberculosis antigen encoding plasmid DNA (pDNA). The formulations included  
(1) trimethyl chitosan (TMC) nanoparticles, (2) a squalene-in-water nanoemulsion, and  
(3) a mineral oil-in-water nanoemulsion. The adjuvant effect of the pDNA-nanocomplexes 
was evaluated by serum antibody analysis in immunized mice. All three carriers display  
a strong adjuvant effect, however, only TMC nanoparticles were capable to bias immune 
responses towards Th1. pDNA naturally contains immunostimulatory unmethylated CpG 
motifs that are recognized by Toll-like receptor 9 (TLR-9). In mechanistic in vitro studies, 
activation of TLR-9 and the ability to enhance immunogenicity by simultaneously 
targeting TLR-9 and NOD-like receptor 2 (NLR-2) was determined by proinflammatory 
cytokine release in RAW264.7 macrophages. pDNA in combination with MDP was shown 
to significantly increase proinflammatory cytokine release in a synergistic manner, 
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dependent on NLR-2 activation. In summary, novel pDNA-Ag85A loaded nanoparticle 
formulations, which induce antigen specific immune responses in mice were developed, 
taking advantage of the synergistic combinations of TLR and NLR agonists to increase the 
adjuvanticity of the carriers used. 
Keywords: adjuvants; toll-like receptor; NOD-like receptor; cationic nanoparticles; DNA 
vaccine; muramyl dipeptide 
 
1. Introduction 
Vaccination by direct injection of antigen encoding plasmid DNA (pDNA) has been evaluated for 
decades. Several preclinical studies have revealed that DNA vaccines can trigger not only humoral but 
also cell-mediated immunity in animals [1]. DNA vaccines usually consist of a bacterial plasmid 
vector genetically modified to express selected antigens of the pathogen in the absence of the other 
bacterial components present in traditional live or attenuated vaccines. However, although proven to be 
usually safe and well tolerated in clinical trials, first-generation DNA vaccines failed to demonstrate 
sufficient vaccine-specific immunogenicity in humans [2–4]. One hypothesis for the low 
immunogenicity of DNA vaccines is suboptimal delivery of the plasmids to antigen presenting cells 
(APCs). Current research focuses on developing novel strategies to improve immunogenicity by 
formulating pDNA with delivery systems and novel specific adjuvants [5,6]. Among these systems, 
particle-based adjuvants of high loading capacity act as delivery vehicles for pDNA to enhance 
plasmid stability and uptake into cells [7,8]. Moreover, versatility of particulate carriers in terms of 
size, surface charge, and material used, enables tailoring toward the desired outcome of immune 
responses [9–11]. Another potential advantage of nano- and microparticles is the induction of local 
chemotaxis to the immunization site due to the promotion of a depot effect [12]. Adsorbing pDNA at 
the outer surface of diverse cationic nanoparticles may lead to the avoidance of steric shielding effects 
by pDNA encapsulation, while conserving the adjuvant effects of nanoparticles. 
Three cationic nanocomplexes offering different structural characteristics were chosen for this 
study: N-trimethyl chitosan (TMC) nanoparticles, a cationic squalene-in-water nanoemulsion (named 
SWE06), and the commercially available cationic nanoemulsion, Cationorm®. These particles were 
compared for their adjuvant potential to increase immunogenicity of pDNA in mice. Chitosan-based 
particles have been used previously as DNA delivery systems, with pDNA entrapped inside the 
nanoparticles, maintaining the cationic surface charge, which may be beneficial for mucosal application 
of DNA vaccines [13,14]. However, previous studies in our laboratory using such formulations did not 
demonstrate higher immunogenicity over non-adjuvanted pDNA, when administered intramuscularly 
in mice. The strong electrostatic charge interaction of condensed pDNA with the cationic polymer may 
interfere with DNA release once the polyplex is taken up by the target cells. 
Squalene based oil-in-water emulsions have already been approved for human use in influenza vaccines 
and are well characterized [15,16]. The cationic phospholipid 1,2-dioleoyl-3-trimethylammonium-propane 
(DOTAP) was added to the hydrophobic phase of the squalene-in-water nanoemulsion (SWE06) to 
obtain positively charged oil droplets. Cationorm® obtained a marketing authorization in Europe for 
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the treatment of dry eye syndrome and was chosen as a third type of nanoformulation in our studies. It 
is known to be safe in ophthalmic applications and was therefore considered as a representative 
example for inert mineral oil-in-water nanoemulsions, with cetalkonium chloride accounting for the 
positive charge [17]. 
DNA vaccines promote exogenous major histocompatibility complex (MHC) class II-restricted, as 
well as endogenous MHC class I-restricted antigen presentation. The latter process mimics antigen 
processing induced by intracellular pathogens such as Mycobacterium tuberculosis (Mtb) [18], against 
which cellular immunity, including proinflammatory cytokines and Th1 cells are believed to play a 
pivotal role. Among Th1 cytokines, interferon gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α) 
have been identified as the most important agents in mycobacterial control, acting synergistically in the 
activation of macrophages [19,20]. The innate immune system has evolved to recognize conserved 
pathogen-associated molecular patterns (PAMPs) by pattern recognition receptors (PRRs). These are 
mainly represented by Toll-like receptors (TRLs) and NOD-like receptors (NLRs), which contribute to 
the host’s ability to eliminate the pathogen. PRR stimulation activates the production of 
proinflammatory cytokines that possess immunoregulatory functions by bridging innate resistance and 
antigen-specific adaptive immune responses [21]. Recognition of bacteria, as well as vaccination with 
live attenuated vaccines, induces activation of multiple PRRs, triggering different signaling pathways, 
which has been shown to be more effective in establishing immune responses than activation of a 
single pathway alone [22]. Unmethylated CpG sequences present on bacterial pDNA are recognized by 
endosomal membrane-bound TLR-9, whereas muramyl dipeptide (MDP), a bacterial cell wall component, 
stimulates cytosolic NLR-2. TLR-9 activates the MyD88-dependent pathway, while NLR-2 activation 
leads to recruitment of receptor-interacting protein 2 (RIP-2) kinase [23,24]. There is documentation on 
cross-talk of TLR and NLR signaling through RIP-2, demonstrating extensive activation of immune cells 
in a synergistic manner by simultaneous co-activation of these two pathways [25–28]. 
In an in vivo experiment in mice we compared TMC nanoparticles, SWE06, and Cationorm® as 
pDNA delivery systems to increase Th1 related immune responses against Ag85A. Following these 
investigations, we then exploited the potential of concurrent activation of two non-redundant PRR 
pathways in vitro with the aim of further optimizing immunogenicity of pDNA. Our results show that 
cationic TMC nanoparticles are promising carriers for pDNA and co-delivery with MDP can be used 
to further increase immunogenicity of this DNA vaccine formulation. 
2. Results and Discussion 
2.1. Nanoparticle Characterization 
The formulations were characterized for their size by differential laser light scattering (DLS) 
expressed as Z-average (nm), polydispersity index (PDI), and their charge as zeta potential (mV), as 
shown in Table 1. The mean hydrodynamic diameter of the unloaded polymer complexes and 
nanodroplets was between 133 and 216 nm (PDI ≤ 0.2) and their surface charge was positive, ranging 
between +18 and +31 mV. After adsorption of pDNA, the size increased for TMC nanoparticles  
(p < 0.001) and both nanoemulsions (p < 0.0001), while the zeta potential decreased drastically to  
7 mV (TMC nanoparticles), −14 mV (SWE06) and −39 mV (Cationorm®). The addition of MDP did 
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not have any influence on size and zeta potential of TMC nanoparticles and SWE06. However, size 
increase and higher PDI values of pDNA loaded Cationorm® with MDP indicated aggregation 
tendencies of this formulation. PDIs between 0.1 and 0.5 were observed for all particles, corresponding 
to systems of mid-range polydispersity [29]. Only small amounts of pDNA were found in the 
supernatant, having measured pDNA adsorption of 99.8% to TMC nanoparticles, 95% to SWE06, and 
93% to Cationorm® of initially added 50 μg/mL pDNA to the cationic nanocomplexes. 
Table 1. Physicochemical properties of trimethyl chitosan (TMC) nanoparticles, a cationic 
squalene-in-water nanoemulsion (SWE06) and Cationorm®, either unloaded or loaded with 
pDNA, muramyl dipeptide (MDP), or both. To determine size in nm, polydispersity index 
(PDI), and zeta potential (ζ) in mV, samples were prepared in water and diluted with 1 mM 
NaCl prior to measurements. 
Loaded with 
TMC Nanoparticles SWE06 Cationorm® 
Size (nm) PDI ζ (mV) Size (nm) PDI ζ (mV) Size (nm) PDI ζ (mV) 
(blank) 216 ± 2 0.1 31 ± 2 133 ± 2 0.1 27 ± 1 157 ± 3 0.2 18 ± 1 
pDNA 252 ± 5 0.2 7 ± 5 188 ± 3 0.1 −14 ± 1 205 ± 2 0.3 −39 ± 0.5
MDP 215 ± 0.5 0.2 32 ± 4 134 ± 2 0.2 26 ± 1 156 ± 2 0.2 14 ± 0.2 
pDNA and MDP 259 ± 3 0.2 4 ± 5 189 ± 3 0.2 −16 ± 1 267 ± 12 0.5 −41 ± 1 
Particle size calculations from electron microscopy imaging confirmed the measurements of 
hydrodynamic diameters of empty nanocarriers by DLS (Figure 1). Mean diameters determined by 
electron microscopy were slightly smaller than determined by DLS (192 ± 28 nm for TMC 
nanoparticles, 114 ± 37 nm for SWE06 and 126 ± 21 nm for Cationorm®). This might be due to shrinking 
during preparation, which can affect the measurements of particle diameters [30]. TMC nanoparticles 
were of globular shape (Figure 1a), whereas the emulsions droplets were of subangular shape  
(Figure 1b,c). Upon pDNA adsorption TMC nanoparticles appeared to deform by loosening the 
electrostatically formed structure (Figure 1A). pDNA at the external site of nanoemulsion droplets 
make them distract, presumably due to charge repulsion, resulting in appearance of single droplets and 
small groups of droplets (Figure 1B). Repulsion was also observed within pDNA loaded Cationorm®, 
however to a lesser extent (Figure 1C). 
Figure 1. Cont. 
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Figure 1. Scanning electron microscopy (SEM) images of plain TMC nanoparticles alone 
(a) and loaded with pDNA (A), transmission electron microscopy (TEM) images of 
SWE06 alone (b) and loaded with pDNA (B), and TEM images of Cationorm® alone (c) 
and loaded with pDNA (C). The scale bars represent a size of 200 nm. 
2.2. Adjuvant Effect of pDNA-Nanoformulations in Vivo 
In this first experiment, performed in mice, we evaluated TMC nanoparticles, SWE06 and 
Cationorm® applied with Mtb antigen Ag85A encoding pDNA for their potential to increase Mtb 
antigen-specific Th1 related immune responses of a tuberculosis DNA vaccine candidate.  
Ag85A possess enzymatic mycolyltransferase activity involved in cell wall synthesis and belongs to 
the key immunodominant antigens of Mtb. We decided to apply the same formulation preparations as 
described above but with a higher quantity of pDNA applied (50 μg per dose) to ensure a detectable 
magnitude of antigen-specific antibodies. The influence of the nature of the nanocomplexes on the 
outcome of elicited immune responses in mice, dependent on the nature of the delivery systems was 
evaluated. The loading efficiency of pDNA to the nanoparticles within these formulations was 43% to 
44%, while surplus pDNA remained in suspension. 
Antigen specific total IgG responses to pDNA in the adjuvanted groups were higher than those 
observed for naked pDNA. In TMC nanoparticle vaccinated mice significantly increased titers of total 
IgG were observed in comparison with pDNA alone, as shown in Figure 2A (p < 0.05). Oil-in-water 
emulsions based on squalene or mineral oils reportedly induce Th2 responses in protein vaccines [31,32]. 
Formulated with DNA both nanoemulsions tested promoted increase in Ag85A specific antibodies to 
pDNA without altering the balanced Th1/Th2 responses observed with naked pDNA (Figure 2). 
TMC nanoparticle adjuvanted pDNA delivery induced a clear bias of Th activation towards type 1, 
which was indicated by detection of ratios of serum IgG2b/IgG1 (Figure 2B) and IgG2c/IgG1  
(Figure 2C) titers above unity. According to the literature, the adjuvant effect of TMC and chitosan on 
Th1/Th2 balance seems to be highly dependent on the antigen applied, route of administration, or 
formulation as particles [33]. Chitosan itself reveals Th2 adjuvant effects [34,35], which are shifted 
towards Th1 when formulated as particles [36,37]. Moreover, although we did not investigate the 
physical interaction between CpG containing pDNA, a TLR-9 ligand, and TMC, the physicochemical 
properties of chitin derivatives, known to activate PRRs such as TRL-2, Dectin-1, and the mannose 
receptor could mediate such interactions [38]. Presumably increase in Th1 type responses is dependent 
on the triggering of distinct intracellular signaling MyD88 dependent and independent pathways, 
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which then merge to activate NF-κB, as has been demonstrated following stimulation of mannose 
receptors and TLR-2 in parallel to TLR-9 stimulation [39]. Whether this Th1 polarization results from 
the physical association of pDNA with TMC or the effect of enhanced uptake of pDNA through 
particle mediated delivery, remains to be determined. Our experiments suggest that formulation of 
pDNA with adjuvants may be necessary to impart Th1 adjuvanticity. 
 
Figure 2. Immune responses in mice to pDNA (50 μg per dose) with/without TMC 
nanoparticles one week after the second booster injection (i.m.). Ag85A-specific serum 
immunoglobulin G (IgG) titers were analyzed by endpoint enzyme-linked immunosorbent 
assay (ELISA). (A) Bars represent mean n = 4 ± SEM, * p < 0.05, compared to pDNA 
alone. (B,C) Corresponding average Log IgG2b/Log IgG1 and Log IgG2c/Log IgG1 ratios 
are indicative for the quality of the immune response, where values higher than 1 (dotted 
line) characterize Th1 biased immune responses. 
2.3. Cell Viability 
Cell viability after exposure to the different particle formulations for 24 h in culture were confirmed 
with XTT assay including Trypan blue dye exclusion, as shown in Figure 3. It has been proposed that 
cationic nanoparticles interact with the cell membrane and may cause damage by membrane 
disruption, leading to cell death [40]. Therefore investigation of the potential toxicity of the cationic 
nanoformulations is important in order to exclude biological responses due to cell death and to assess 
safety concerns for future in vivo applications. When uncomplexed TMC polymer was applied to the 
cells, reduced cell viability was observed (data not shown). Chondroitin sulfate partially balanced the 
cationic charge of TMC and, as a consequence, cell viability to the resulting nanoparticles increased. 
This is in accordance with other studies that showed less toxicity upon charge neutralization with 
anionic agents or pDNA [41,42]. 
No significant toxicity was detected for any of the nanoformulations, either unloaded, pDNA and/or 
MDP loaded, compared to the untreated control cells (viability >80% in all cases). For TMC 
nanoparticles and SWE06 emulsions cell viability was slightly increased with pDNA loading 
compared to the unloaded formulations, which may be due to neutralization of cationic surface charges 
known to be linked to better biocompatibility [43]. 
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Figure 3. Cell viability of RAW264.7 macrophages, detected with XTT reagent, after 24 h 
of incubation with the following formulations: unloaded TMC nanoparticles, SWE06 and 
Cationorm® (∘) and each nanoformulation loaded either with pDNA (∗), MDP (▲), or 
pDNA + MDP (⋄). Percentages above 80% (dotted line) were considered as minimum 
levels of acceptable viability. 
2.4. In Vitro Activation of TLR-9 and NLR-2 
In subsequent mechanistic experiments on RAW264.7 murine macrophages the inherent adjuvant 
effect of unmethylated CpG containing pDNA in combination with MDP as an additional 
immunostimulator, delivered with all three cationic nanocomplexes, was investigated to potentially 
further optimize cell-mediated immunity by simultaneous innate immune activation. pDNA adsorbed 
to nanoparticles and nanoemulsions were formulated with MDP and studied for their ability to release 
proinflammatory cytokine TNF-α. Synergistic enhancement of immune response by two PRR ligands 
was investigated using CpG islet containing pDNA for TLR-9 stimulation, and MDP as a NOD2 
ligand. Emerging evidence suggests cooperative effects of PRRs [44]. Consequently, we also 
investigated the outcome of combined stimulation of the TLR and NLR systems. Neither pDNA nor 
MDP alone could substantially activate macrophages as shown in Figure 4. TMC nanoparticles loaded 
with pDNA were shown to significantly increase cytokine release, compared to pDNA alone  
(p < 0.001). Carrier function for Cationorm® appeared to be less important and SWE06 even decreased 
TNF-α release induced by pDNA alone (p < 0.01). When we combined both ligands in one formulation, 
the NOD2 ligand MDP augmented pDNA-induced activation of murine macrophages in vitro by up to 
4-fold, with a significant increase of TNF-α release compared to naked pDNA (p < 0.001) or pDNA 
adsorbed to nanocarriers (TMC nanoparticle p < 0.01, SWE06 p < 0.001, Cationorm® p < 0.01).  
This indicates that MDP has an influence on enhancing immune responses in a synergistic manner with 
the TLR ligand, as cytokine production by the combination of immune receptor ligands was higher 
than production of each of the single stimulations and as the sum of each effect individually.  
The adjuvant function of TMC nanoparticles seemed to be most important for the co-delivery of 
pDNA and MDP in one formulation. TMC nanoparticles were the only carriers for pDNA and MDP 
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that were shown to be significantly superior in stimulating cytokine release when compared to the 
ligands combined in solution (p < 0.01). 
 
Figure 4. Tumor necrosis factor-alpha (TNF-α) release from RAW264.7 murine 
macrophages on exposure to different stimulating agents: pDNA and MDP applied either 
alone or in combination in solution, or with TMC nanoparticles (TMC-NP), SWE06, and 
Cationorm®, respectively. Bars represent mean values (n = 3) ± SEM. pDNA loaded 
nanoformulations were compared with either pDNA alone (*) or with [pDNA + MDP] 
loaded nanoformulations (*), and [pDNA + MDP] in solution with [nanocarrier + pDNA + 
MDP] (x). Significant differences were indicated with ** (p < 0.01), *** (p < 0.001), and 
ns (not significant). 
TLR-9 specifically recognizes unmethylated or hypomethylated CpG islets, prevalent in bacterial 
and many viral DNAs [45]. To confirm that TNF-α response is dependent on TLR-9 activation, 
macrophages were stimulated with pDNA either containing or lacking CpG motifs. To further assure 
that the cytokine response is also dependent on NLR-2 activation the inactive D-isoform of MDP was 
applied in the same experiment. The dependency on PRR activation to induce a distinct TNF-α 
response towards TLR-9 and NLR-2 ligands implemented in the experiments is shown in Figure 5. 
Nanoparticles loaded with inactive control ligands were found to not induce cytokine release, 
compared to the unloaded nanocarriers. Significant decrease of cytokine release was observed for 
inactive control ligands transported by TMC nanoparticles, SWE06 and Cationorm®, compared to their 
active forms. Cells were minimally stimulated with TMC and CpG-free pDNA containing inactive 
control samples. This could be due to inherent adjuvant effects of TMC that possibly derives from the 
chitosan’s molecular features to activate PRRs [46]. Furthermore, there may be potential contributions 
to immune activation by pDNA by other elements than TLR-9 activation via unmethylated CpG, such 
as cytosolic TANK-binding kinase-1 activation by the double stranded B-form of pDNA [47].  
Mineral oil based incomplete Freund’s adjuvant as well as squalene-based formulations have been 
shown to polarize the immune response toward the production of anti-inflammatory cytokines [48,49]. 
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This may mask the TNF-α increasing effect by the double stranded nature of CpG-free pDNA, as well 
as of the active ligands, applied with SWE06 and Cationorm®, respectively. 
 
Figure 5. TNF-α release from RAW264.7 murine macrophages treated with pDNA and/or 
MDP and their inactive controls pCpGfree and/or D-MDP, respectively. The ligands were 
applied either in solution, as single components, or combined with TMC nanoparticles 
(TMC-NP), SWE06, or Cationorm®, respectively. Significantly reduced activity by control 
ligands compared to their active ligands are indicated with ** (p < 0.01), *** (p < 0.001), 
and **** (p < 0.0001). 
2.5. NLR-2 Dependent Synergistic Enhancement of TNF-α Release 
NLR-2 activation was inhibited in order to demonstrate its influence during co-stimulation with 
TLR-9 ligand on the synergistic enhancement of immune responses. Cells incubated with pDNA and 
MDP were treated with or without RIP-2 tyrosine kinase inhibitor gefitinib, to study NOD2 synergy 
with pDNA. The mechanism of the cross-talk between the pathways for PRRs is not yet fully 
understood, but it has been shown that there are functional links between protein RIP2 and both 
pathways of TLR and NLR (Chin 2002, Kobayashi 2002). If synergistic enhancement is dependent on 
interaction between RIP2, activated by NOD2, and MyD88 of the TLR pathway, then inhibition of 
RIP2 kinase may serve to correct the excessive activation seen with combination of pDNA + MDP [50]. 
Indeed, we showed that RIP2 blocking led to significant reduction of cytokine release, leading to 
reduced cytokine release for ligands applied in solution (p < 0.05), for TMC nanoparticle-conjugates  
(p < 0.01) and for ligands applied with SWE06 (p < 0.001) and Cationorm® (p < 0.01) nanoemulsions, 
respectively, compared to untreated cells (Figure 6). The diminished macrophage activation was shown 
to be similar to that induced by pDNA alone or pDNA applied with the nanocarriers without MDP. 
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Figure 6. TNF-α release from RAW264.7 murine macrophages treated with or without 
RIP2 tyrosine kinase blocker gefitinib. Stimulants were pDNA and MDP in combination, 
applied either in solution or with TMC nanoparticles, SWE06, or Cationorm®, respectively. 
Significantly reduced activity by receptor-interacting serine/threonine-protein kinase 2 
(RIP2) blocking compared to unblocked NLR-2 pathway are indicated with * (p < 0.05), 
** (p < 0.01), and *** (p < 0.001). 
3. Experimental Section 
3.1. Materials 
Chitosan (ChitoClear Cg10, 79% degree of deacetylation, 7–15 mPa·s) was purchased from Primex 
(Siglufjordur, Iceland). Methyl iodide, chondroitin sulfate and bovine serum albumin (BSA, endotoxin 
<0.1 ng/mg) were obtained from Sigma-Aldrich (Buchs, Switzerland). DOTAP was purchased from 
Avanti Polar Lipids (Alabaster, AL, USA) and Cationorm® (Novagali Pharma, Evry, France) was 
purchased at a local pharmacy. Double stranded 5853 bp pDNA encoding Ag85A was provided by the 
Institute Pasteur (Brussels, Belgium), propagated in NovaBlue competent cells (Merck, Darmstadt, 
Germany) that were kindly provided by Scapozza (University of Geneva, Geneva, Switzerland). The 
plasmid was then purified by using an Endofree Plasmid Giga Kit (Qiagen, France) according to the 
manufacturer’s protocol and suspended in PBS. Goat anti-mouse total IgG, IgG1, IgG2b and IgG2c 
conjugated to horseradish peroxidase (HRP) was obtained from Southern Biotech (Birmingham, AL, 
USA) and 3,3′,5,5′-Tetramethylbenzidine (TMB) substrate from Becton Dickinson (San Diego, CA, 
USA). All cell culture reagents were provided by Life technologies (Zug, Switzerland) and  
Sigma-Aldrich (Buchs, Switzerland), and XTT-cell proliferation kit II was bought from Roche (Basel, 
Switzerland). MDP, as well as LPS-EB, CpG-free pDNA (pCpGfree-giant) and inactive MDP  
(D-MDP) as controls, and RIP-2 tyrosine kinase inhibitor gefitinib were purchased from Invivogen 
(San Diego, CA, USA). For proinflammatory cytokine detection in cell supernatants, mouse TNF-α 
ELISA Ready-SET-Go! Kit was obtained from eBioscience (Paris, France).  
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3.2. Preparation of Nanoparticle Formulations 
TMC nanoparticles: TMC was synthesized from chitosan by quaternisation of the amino groups 
based on the method first published by Domard et al. [51], and later modified by Heuking et al. [52]. 
In this procedure only one methylation step was employed for the synthesis of TMC. Briefly, 2 g of 
high molecular weight chitosan of crustacean origin were trimethylated through nucleophilic substitution 
by addition of 12 mL methyl iodide for 70 min at 60 °C under reflux. TMC nanoparticles were 
prepared by polyelectrolyte complexation with chondroitin sulfate according to Schatz et al. [53]. 
TMC (5 mg/mL) and chondroitin sulfate (1 mg/mL) were solubilized separately in water at room 
temperature and filtered through 0.22 μm syringe filters (Millipore AG, Zug, Switzerland). Then,  
0.5 mL of each polymer solution was mixed, briefly vortexed at high speed, and the resulting 
nanoparticle suspension diluted 1:10 with the appropriate media. In case of nanoparticles containing 
MDP, the dipeptide was mixed with the TMC solution before particle formation. The final MDP 
concentration per ml of nanoparticle suspension was 30 μg. For pDNA adsorption, 50 μg/mL of the 
plasmid were incubated for 15 min at 4 °C with the TMC nanoparticle suspensions. 
SWE06 and Cationorm® nanoemulsions: SWE06, a cationic squalene-in-water nanoemulsion, was 
manufactured by the Vaccine Formulation Laboratory at the University of Lausanne (Epalinges, 
Switzerland) and contained 0.1% DOTAP, 3.9% (w/v) squalene, 0.5% (w/v) Tween® 80 and 0.5% 
(w/v) Span® 85 in saline. Cationorm® was developed by Novagali Pharma (now Santen), an oil-in-water 
nanoemulsion composed of 0.1% poloxamer 188, 0.3% tyloxapol, 0.002% cetalkonium chloride, 1% 
mineral oils and 1.6% glycerol in Tris hydrochloride buffer as indicated in the decision report of the 
French National Authority for Health [54]. Both nanoemulsion formulations were diluted at a ratio of 
1:100 with the appropriate media prior to each experiment. pDNA was incubated for 15 min at 4 °C 
with the diluted nanoemulsions to obtain electrostatic binding of pDNA to the cationic nanodroplets 
and a final pDNA concentration of 50 μg/mL. For the MDP-containing nanoemulsion formulations, 
the dipeptide was simply mixed with the diluted emulsion to obtain a final concentration of 30 μg/mL, 
then vortexed at high speed, and immediately applied in the experiments. 
All three nanoparticle suspensions (TMC, SWE06 and Cationorm®) showed an endotoxin level  
<1 EU/mL as tested by Endosafe® Test Record. 
3.3. Characterization of Nanoparticles 
3.3.1. Particle Size, Zeta Potential and Morphology of Nanocarriers 
Hydrodynamic diameters and polydispersity index (PDI) were determined by dynamic light 
scattering (DLS) measurements and zeta potential by electrophoresis and laser light scattering using  
a Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK). Samples were prepared as described 
above and diluted ten times in 1 mM NaCl to achieve a constant ionic background and measured at  
25 °C in clear disposable zeta cells. 
The morphology of dried TMC nanoparticles was imaged with scanning electron microscopy 
(SEM; Jeol JSM-7001FA, Tokyo, Japan) at an accelerating voltage of 15 kV. The samples were  
1000-fold diluted with water, placed on a grid, and air-dried overnight under vacuum. The grids were 
sputter coated with 10 nm gold under vacuum before imaging (Leica EM SCD 500, Heerbrugg, 
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Switzerland). SWE06 and Cationorm® nanoemulsions were stained with uranyl acetate and their 
morphology examined by transmission electron microscopy at 200 kV (TEM; Tecnai G2 T20 Sphera, 
FEI, Hillsboro, OR, USA). 
To assess the particle area and radius, microscopic images were analyzed using ImageJ 1.46r 
software (National Institute of Health, Bethesda, MD, USA). Assuming that the nanostructures are 
roughly spherical, their radii were calculated from the particle areas, and subsequently their diameters, 
according to Equation (1): 
r = ඨAπ  (1)
3.3.2. Loading Efficiency 
The adsorption rate of pDNA onto nanoparticles was evaluated, measured under conditions 
corresponding to the in vitro studies as well as to the in vivo studies. Nanoparticle suspensions with 
pDNA were prepared as described above and centrifuged at 14,000 rpm for 15 min (Eppendorf 5810R, 
Vaudaux-Eppendorf, Basel, Switzerland). Unloaded pDNA in the supernatant was quantified by 
PicoGreen assay according to the manufacturer’s protocol. A calibration curve was established by 
plotting the fluorescence intensity of each standard against the concentration series. The samples were 
excited at a wavelength of 480 nm and the fluorescence emission intensity was measured at 520 nm 
using a fluorescence microplate reader (Tecan Group Ltd., Männedorf, Switzerland). The amount of 
pDNA adsorbed on TMC nanoparticles or nanoemulsions was calculated by subtracting the pDNA 
quantity found in the supernatants or in the oil phase after centrifugation, from the amount of pDNA 
initially added. 
3.3.3. In Vivo Immunogenicity of pDNA-nanoformulations 
Female C57BL/6 mice (Harlan, Itingen, Switzerland) were maintained under standardized 
conditions in the animal facility of the University of Lausanne (Epalinges, Switzerland). The study was 
performed in compliance with the Swiss Federal Veterinary Office guidelines (Authorization 2475, 
SCAV, Lausanne, Switzerland). The formulations were prepared as described above, diluted with 
phosphate buffered saline (PBS) and Ag85A encoding pDNA at a final concentration of 50 μg per dose 
was added to the diluted nanoparticles and nanoemulsions. Eight-week-old mice (n = 4 per group) 
were immunized on Days 0, 21, and 42 with a dose of 50 μL by intramuscular administration in the 
hind limb. The mice were bled 1 week after the third immunization by cardiac puncture and sera were 
stored at −20 °C. Anti-Ag85A-specific serum IgG titers and IgG isotypes 1, 2b, and 2c were 
determined by ELISA at the endpoint of the optical density-log dilution curves. Non-responding mice 
were given an arbitrary titer of 1. Briefly, 96-well microtiter plates (Nunc, Roskilde, Denmark) were 
coated with 1 μg/mL rAg85A in PBS overnight at 4 °C, followed by blocking of the wells with 1% 
(w/v) BSA in PBS for two hours at room temperature (RT) to reduce nonspecific binding and 
subsequent addition of serial dilutions of serum ranging from 102 to 2.2 × 105 for one hour at RT. 
Ag85A specific antibodies were detected by incubating HRP conjugated goat anti-mouse IgG, IgG1, 
IgG2b or IgG2c (1 h, RT) and by developing plates with TMB for 5 min at RT in the dark. The 
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reaction was stopped with 1 N sulfuric acid and absorbance was determined at 450 nm with an iMARK 
micro plate reader (Bio-Rad Laboratories, Hercules, CA, USA). 
3.3.4. Cell Culture 
The murine macrophage cell line RAW264.7 was obtained from American Type Culture Collection 
(ATCC, Rockville, MD, USA). Cells were cultured in cell culture medium based on DMEM, 
supplemented with 10% heat-inactivated fetal calf serum (FCS) and 1% penicillin/streptomycin, at  
37 °C in an atmosphere containing 5% CO2. Cells were seeded at an initial density of 3 × 104 cells per 
well in a 96-well plate, if not indicated otherwise. 
3.3.5. In Vitro Cytotoxicity and Cytokine Release Assays 
Potential cytotoxic effects of the nanoparticle formulations were evaluated by XTT assay to 
determine cell viability following nanoparticle exposure. RAW264.7 cells were cultured with the 
nanoformulations suspended in FCS containing cell culture media for 24 h. Additionally, positive 
controls were run in parallel, SDS 0.2% for cytotoxicity and LPS (5 μg/mL) for proinflammatory 
cytokine release. The cell supernatants were withdrawn for cytokine analysis, replaced by XTT reagent 
and incubated for another 5 h at 37 °C. The mean OD value of the wells was determined by measuring 
at a wavelength of 490 nm using a microplate spectrophotometer reader (Power Wave XS, Biotek, 
France) and corrected by the blank value. The relative cell viability was expressed as a percentage 
relative to untreated control cells cultured under the same conditions. 
Cell supernatants from the cell viability assay as described above were centrifuged at 300× g for  
5 min and frozen at −80 °C prior to analysis. TLR-9 and NLR-2 control samples included nanoparticle 
complexes, formed with pCpG-free pDNA and D-MDP. Both control ligands were applied at the same 
concentrations as pDNA and MDP, respectively. For NLR-2 pathway inhibition, cells were pretreated 
with 100 nM gefitinib for 1 h before stimulation with the nanoparticle formulations. Cell supernatants 
of all cytokine release experiments were diluted 1:10 and TNF-alpha induction determined by mouse 
TNF-α sandwich ELISA, according to the manufacturer’s instruction. Cytokine concentrations were 
calculated against a standard curve prepared in duplicates. 
3.3.6. Statistical Analysis 
The statistical significance for in vitro experiments measuring TNF-α release, was assessed by 
Student’s t-test for two samples, assuming equal variance. Experiments were repeated at least once and 
data evaluated are mean values of triplicate samples. Statistical analysis was performed following 
logarithmic transformation of antibody titers. The statistical significance for in vivo data measuring 
IgG antibody titers was assessed by a two-tailed Mann–Whitney test (n = 4). The statistical analysis 
was carried out using GraphPad Prism 6 software (GraphPad, San Diego, CA, USA) and p values less 
than 0.05 were considered to be significant. 
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4. Conclusions 
Polymeric TMC nanoparticles were compared with squalene-in-water and mineral oil-in-water 
nanoemulsions for delivery of Mtb antigen Ag85A encoding pDNA to induce antigen-specific immune 
responses in vivo. Among the three nanoformulations evaluated, TMC nanoparticles were identified as 
the best candidate for polarizing immune responses to Th1, which is desirable in inducing immunity 
against Mtb infections. Subsequently, optimization of the pDNA-nanoformulations with MDP was 
investigated in mechanistic in vitro studies. We showed that simultaneous targeting of TLR-9 by 
unmethylated CpG motifs present in pDNA and NLR-2 by MDP results in significantly increased 
proinflammatory cytokine release in a synergistic manner. In conclusion, TMC nanoparticles were 
shown to be promising carriers for pDNA to polarize immunity towards cell-mediated immune 
responses. Our in vitro investigations revealed the potential of co-delivery with MDP that can  
be taken into consideration in future in vivo studies to further increase immunogenicity of these DNA 
vaccine formulations. 
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